


IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Applicant : Chikara MURAKATA et al.

Confirmation No. 8988

Group Art Unit: 1614

Serial No. : 10/553,222
(National Stage of PCT/JP2004/005489)

Examiner: unknown

Filed : October 17, 2005 (I.A. Filed: April 16, 2004)

For : MITOTIC KINESIN INHIBITOR

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner of Patents
U.S. Patent and Trademark Office
Customer Service Window, Mail Stop Amendment
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

Further to the Information Disclosure Statement filed September 1, 2006, and in accordance with the duty of disclosure under 37 C.F.R. § 1.56 and 37 C.F.R. §§ 1.97-1.98, Applicants hereby direct the Examiner's attention to the following copending and commonly assigned U.S. patent application:

- (1) U.S. Application No. 10/575,093 to MURAKATA et al., filed December 7, 2006 and entitled "THIADIAZOLINE DERIVATIVE", which is a U.S. National Stage Application of PCT/JP2004/015293.

Applicants further direct the Examiner's attention to the following documents cited in the International Search Report for International Application PCT/JP2004/015293:

- (2) B. G. Szczepankiewicz et al., J. Med. Chem., 2001, Vol. 44, No.25, pp. 4416-4430;
- (3) S. M. Hassan et al., J. Chem. Research Synopses, 2000, Vol. 12, pp. 544-545 and pp. 1301-1315; and
- (4) K. N. Zelenin et al., Zhurnal Organicheskoi Khimii, 1984, Vol. 20, No.1, pp.152-162 .


Applicants note that the documents cited in the International Search Report for International Application PCT/JP2004/015293 that are not listed herein were brought to the Examiner's attention in a previous Information Disclosure Statement.

Copies of the above-listed documents and the International Search Reports (in English) for International Application PCT/JP2004/015293 and its corresponding International Preliminary Report on Patentability are enclosed together with a completed copy of the PTO-1449 Form listing these documents. The Examiner is requested to consider these documents and to indicate such consideration by returning a signed and initialed copy of the PTO-1449 Form with the next official communication.

Applicants note that an Office Action on the merits has not yet issued in the instant application, and thus, no fee is necessary to ensure consideration of this statement. However, if an Office Action has issued and is crossing in the mail with this statement, the Patent and Trademark Office is hereby authorized to charge Deposit Account No. 19-0089 any fee necessary to ensure consideration of the submitted materials.

Should there be any questions, the Examiner is invited to contact the undersigned
at the below listed telephone number.

Respectfully submitted,
Chikara MURAKATA, et al.


Bruce H. Bernstein
Reg. No. 29,027 42,920

April 10, 2007
GREENBLUM & BERNSTEIN, P.L.C.
1950 Roland Clarke Place
Reston, VA 20191
(703) 716-1191

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.
P28672

Application No.
10/553,222

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**
(Use several sheets if necessary)

Applicant
Chikara MURAKATA et al.

Filing Date
October 17, 2005

Group
1614

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	1	U.S. Application No. 10/575,093 to MURAKATA et al., filed December 7, 2006 and entitled "THIADIAZOLINE DERIVATIVE".
	2	B. G. Szczepankiewicz et al., J. Med. Chem., 2001, Vol. 44, No.25, pp. 4416-4430.
	3	S. M. Hassan et al., J. Chem. Research Synopses, 2000, Vol. 12, pp. 544-545 and pp. 1301-1315.
	4	K. N. Zelenin et al., Zhurnal Organicheskoi Khimii, 1984, Vol. 20, No.1, pp.152-162 .

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.